• Blog
  • Cancer Immunotherapy Market Size | 2022-27

    Cancer Immunotherapy Market Size | 2022-27

    Cancer Immunotherapy Market Size | 2022-27
    Report code - SR1999 Delivery - 2 Weeks
    Get Free Sample |
    Cancer Immunotherapy Market Size, Share, Trend, Forecast, Competitive Analysis, and Growth See more...

    Market Insights

    The cancer immunotherapy market is expected to grow at a healthy CAGR of 13.5% from 2022 to 2027. Major factors such as growing adoption of target therapy, rising cancer incidence, and technological advancements in cancer treatment therapies are expected to drive the market growth during the forecast period. Furthermore, rising R&D activities in the field of cancer immunotherapy are likely to underpin the growth of the market over the forecast period. 

    Cancer Immunotherapy Market– Snapshot

    Growth (2022-2027)

    CAGR 13.0%

    Major Diagnosis Type

    Lunch Cancer

    Region with the highest demand

    North America

    Key Players

    • Amgen Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Co.
    • ELI Lilly and Company
    • F Hoffman-La Roche Ltd.
    • Janssen Global Services, LLC (Johnson and Johnson)
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.

    Download a Free sample, Click here.

    Covid Impact analysis
    The COVID-19 pandemic gravely affected the cancer immunotherapy market in 2020. The growth of the market declined due to supply chain disruptions, production halts, and clinical trial delays. The wrath of the pandemic affected the buying capacity of hospitals and scanning centres, which in turn, has had an impact on the cancer immunotherapy market. As a result, the market recorded a decline in the year 2020.

    What is cancer immunotherapy?

    Cancer immunotherapy, also known as immuno-oncology, is a type of cancer treatment that uses a person’s own immune system to prevent, control, and fight cancer. Cancer immunotherapy is a type of biological therapy, that uses substances made from living organisms to boost the immune system in order to eradicate cancer.

    Key Players

    The following are some of the key players in the cancer immunotherapy market:

    • Amgen Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Co.
    • ELI Lilly and Company
    • F Hoffman-La Roche Ltd.
    • Janssen Global Services, LLC (Johnson and Johnson)
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc

    Segment Analysis

    Based on the drugs class type, the market is bifurcated into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, cell therapies, immunomodulators, and interferons alpha. Monoclonal antibodies held the major share of the market in 2021, and are expected to remain the biggest demand generator for the cancer immunotherapy market in the foreseen future. Key factors such as cost effectiveness and increasing investments in R&D of monoclonal antibodies are expected to drive the market growth in the coming years.

    Based on the diagnosis type, the market is segmented as lung cancer, breast cancer, multiple myeloma, colorectal cancer, head & neck cancer, prostate cancer, melanoma, and other cancer types. Lung cancer captured the largest share of the cancer immunotherapy market in 2021, due to factors such as increasing number of patients suffering from lung diseases. The segment is likely to remain dominant during the forecast period, owing to the growing awareness of the early therapeutics of lung cancer.

    Based on the end-user type, the market is segmented as hospitals, clinics, and others. Among these end-user types, hospital dominates the market and is expected to grow with the highest CAGR during the forecast period. Hospitals are highly preferred for cancer immunotherapy, and rising demand for cancer immunotherapy in hospitals is expected to drive the market growth over the forecast period.

    In terms of regions, North America is expected to remain the largest market for cancer immunotherapy over the forecast period. Major factors such as rising incidence of cancer, increasing demand for modern cancer therapeutics, and growing geriatric population are fuelling the growth of the regional cancer immunotherapy market. Asia-Pacific is expected to be the fastest-growing region during the forecast period, due to rise in healthcare expenditure, development in healthcare infrastructure, increasing prevalence of cancer, and rising per capita income.

    The cancer immunotherapy market is segmented into the following categories:

    Cancer Immunotherapy Market, by Drugs Class Type

    • Monoclonal Antibodies (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
    • Cancer Vaccines (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
    • Checkpoint Inhibitors (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
    • Cell Therapies (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
    • Immunomodulators (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
    • Interferons Alpha (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)

    Cancer Immunotherapy Market, by Diagnosis Type

    • Lung Cancer (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
    • Breast Cancer (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
    • Multiple Myeloma (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
    • Colorectal Cancer (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
    • Head & Neck Cancer (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
    • Prostate Cancer (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
    • Melanoma (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
    • Other Cancer Types (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)

    Cancer Immunotherapy Market, by End-User Type

    • Hospitals (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
    • Clinics (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
    • Others (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)

    Cancer Immunotherapy Market, by Region

    • North America (Country Analysis: The USA, Canada, and Mexico)
    • Europe (Country Analysis: Germany, France, The UK, Russia, Italy, and Rest of Europe)
    • Asia-Pacific (Country Analysis: China, Japan, India, South Korea, and Rest of Asia-Pacific)
    • Rest of the World (Country Analysis: Brazil, Argentina, and Others)

    Research Methodology

    This strategic assessment report, from Stratview Research, provides a comprehensive analysis that reflects today’s cancer immunotherapy market realities and future market possibilities for the forecast period of 2022 to 2027.

    The report segments and analyzes the market in the most detailed manner in order to provide a panoramic view of the market.

    The vital data/information provided in the report can play a crucial role for the market participants as well as investors in the identification of the low-hanging fruits available in the market as well as to formulate the growth strategies to expedite their growth process.

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

    More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data.

    We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:

    • Market structure: Overview, industry life cycle analysis, supply chain analysis.
    • Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis.
    • Market trend and forecast analysis.
    • Market segment trend and forecast.
    • Competitive landscape and dynamics: Market share, Product portfolio, New Product Launches, etc.
    • Attractive market segments and associated growth opportunities.
    • Emerging trends.
    • Strategic growth opportunities for the existing and new players.
    • Key success factors.

    Report Customization

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

    Custom Research: Stratview research offers custom research services across the sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@Stratviewresearch.com

    Frequently Asked Questions (FAQs)

    Cancer immunotherapy, also known as immuno-oncology, is a type of cancer treatment that uses a persons own immune system to prevent, control, and fight cancer. Cancer immunotherapy is a type of biological therapy, that uses substances made from living organisms to boost the immune system in order to eradicate cancer.

    The cancer immunotherapy market is estimated to grow at a healthy CAGR of 13.5% during the forecast period, owing to the rising incidence of cancer, increasing demand for cancer immunotherapies, and growing investments by major market players, particularly in emerging economies.

    Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Co., ELI Lilly and Company, F Hoffman-La Roche Ltd., Janssen Global Services, LLC (Johnson and Johnson), Merck & Co., Inc., Novartis AG, and Pfizer Inc. are some of the key players in the market.

    North America is estimated to be dominant in the cancer immunotherapy market in the coming years. Major factors such as increasing healthcare expenditure and the rising incidence of cancer cases in the region are expected to fuel the regional market growth.

    Asia-Pacific is estimated to grow at the fastest rate in the coming five years. Significant investments in healthcare infrastructure coupled with the entry of new players to address the huge market potential drives the overall regions market dynamics.

    Hospital is likely to maintain its dominance in the market in the next five years. Hospitals are highly preferred for cancer immunotherapy, and rising demand for cancer immunotherapy in hospitals is expected to drive the market growth over the forecast period.